Clinical Trials Browser

Phase 2 × Recruiting × Ipilimumab × Clear all

NCT03866382 2026-03-18

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Phase 2 Recruiting

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT05112601 2026-03-18

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Phase 2 Recruiting

Endometrial Neoplasms, Carcinoma, Endometrioid

NCT06708949 2026-03-13

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT03026140 2026-03-05

NICHE

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT03297606 2026-03-04

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT06946797 2026-02-24

CheckMate-1533

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07188896 2026-02-23

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT06999980 2026-02-19

Neo IRENIE

Phase 2 Recruiting

Melanoma

NCT02693535 2026-02-13

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT07230613 2026-02-11

NEOREM-NEO-1

Phase 2 Recruiting

Melanoma

NCT03340129 2026-02-02

ABC-X

Phase 2 Recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04562129 2026-01-29

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Phase 2 Recruiting

Melanoma, Skin Neoplasms

NCT06365619 2026-01-29

NeoRelapse

Phase 2 Recruiting

Melanoma

NCT05327686 2026-01-14

SAMURAI

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT06295159 2026-01-08

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Phase 2 Recruiting

Melanoma

NCT05779423 2026-01-06

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Phase 2 Recruiting

Melanoma, Skin Neoplasms

NCT05428007 2026-01-05

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 Recruiting

Melanoma

NCT04933903 2025-12-30

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04996823 2025-12-04

Axitinib + Ipilimumab in Advanced Melanoma

Phase 2 Recruiting

Melanoma, Skin Neoplasms

NCT06941857 2025-12-03

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Pancreatic Neoplasms

NCT07155317 2025-11-12

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Phase 2 Recruiting

Melanoma

NCT03546686 2025-10-27

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06747845 2025-09-16

ParpVax2

Phase 2 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

NCT06712927 2025-09-08

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Phase 2 Recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06364917 2025-09-03

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03646617 2025-08-13

RadVax

Phase 2 Recruiting

Melanoma

NCT05732389 2025-08-07

RESET-R

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05361720 2025-07-23

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Phase 2 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05310643 2025-07-01

NIPIRESCUE

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03645928 2025-06-19

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2 Recruiting

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03406247 2025-05-08

ADJORL1

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04472767 2025-04-30

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06926790 2025-04-22

GALAXY 3

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06342037 2024-09-19

TONIC-3

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06492421 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03815890 2024-05-30

BELLINI

Phase 2 Recruiting

Breast Neoplasms

NCT05492123 2024-01-05

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT03563729 2023-07-13

MEMBRAINS

Phase 2 Recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03166397 2023-01-26

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Phase 2 Recruiting

Melanoma